BioSite Triage Becomes The First BNP Test To Receive A CLIA Waiver
This article was originally published in The Gray Sheet
Executive Summary
BioSite plans to market its Triage BNP test to the 55,000 physician practices that most often treat heart failure patients after becoming the first BNP test manufacturer to receive a CLIA waiver from FDA
You may also be interested in...
Beckman Coulter Buys Cardiac Test Developer Biosite For $1.55 Billion
In a $1.55 billion acquisition plan announced March 25, Beckman Coulter looks to combine its strength as a leading manufacturer of lab instruments with the complementary expertise of diagnostic test developer Biosite
Beckman Coulter Buys Cardiac Test Developer Biosite For $1.55 Billion
In a $1.55 billion acquisition plan announced March 25, Beckman Coulter looks to combine its strength as a leading manufacturer of lab instruments with the complementary expertise of diagnostic test developer Biosite
People In Brief
Shakeup at FoxHollow: Ron Steckel replaces David Martin as COO, and Richard Zimmer replaces Bill Hoffman as VP-sales. Steckel moves up from senior VP-operations and research & development, where he focused on improving operating efficiency. Zimmer has spent two years with FoxHollow, serving as director of sales since October. The firm recently announced plans for new studies of its SilverHawk plaque excision system (1"The Gray Sheet" Jan. 16, 2006, p. 7). However, FoxHollow's stock has dropped 38.5% from $45.46 on Dec. 12, when the firm announced the resignation of CEO Robert Thomas, to close Feb. 10 at $27.95 (2"The Gray Sheet" Jan. 9, 2006, p. 13)...